Dineurin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dineurin

Quick Facts

Property Description
Active ingredient Gabapentin
Form Capsules, tablets, oral solution
Pharmacological class Anticonvulsant, Anti-epileptic drug
Common use Management of nerve over-activity
Origin Synthetic compound

What Type of Medicine is Dineurin and What Does it Contain?

Dineurin is a prescription medication containing the active substance Gabapentin, which is formally classified as an anticonvulsant or anti-epileptic drug. Chemically, Gabapentin is a synthetic compound derived from a gamma-amino acid and functions as a single-ingredient product. Pharmacological studies have widely supported the role of Gabapentin as a GABA analogue, though its primary mechanism is distinct from direct receptor binding. Instead, the drug achieves its therapeutic effect by binding to the alpha2delta-1 subunit of voltage-gated calcium channels. Dineurin, as a brand, provides this recognized formulation of Gabapentin, typically positioned for use across adult and adolescent patient groups requiring management of excessive nerve signaling.

Dineurin's General Purpose and Available Forms

The general therapeutic purpose of Dineurin is to stabilize and quiet overactive nerve function within the central nervous system, a role clinically recognized for addressing conditions characterized by uncontrolled or excessive neural signaling. This core function is achieved by modulating the flow of calcium ions into nerve endings, which limits the rapid release of excitatory neurotransmitters and thereby diminishes overall neuronal excitability. Dineurin is prepared for oral administration and is available in multiple dosage forms, including hard-shell capsules, film-coated tablets, and an oral solution. This availability in diverse forms offers flexibility for patients who may face difficulties swallowing solid tablets.

Regulatory References

  1. NCBI StatPearls - Gabapentin

What side effects are possible with Dineurin?

Possible Side Effects and Safety Information for Dineurin

This section outlines the documented adverse reactions and key safety elements for Dineurin, structured according to official government regulatory documentation. Note that specific, verifiable adverse reaction data for Dineurin from major international drug authorities (such as the FDA, EMA, or Health Canada) is not publicly available in the search results.

Adverse Reaction Scope

The regulatory safety profile typically organizes possible side effects into categories based on two main criteria:

  • Frequency Classification: Side effects are formally classified according to how often they occur (e.g., Very Common, Common, Uncommon, Rare) as observed in clinical trials or post-marketing surveillance. This standardized framework allows users to understand the likelihood of a specific reaction.
  • System-Organ Class (SOC): Adverse effects are grouped by the major body system they affect (e.g., Nervous System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders).

Serious Adverse Reactions

Official regulatory documents specifically identify reactions that are considered medically serious or clinically significant. This includes adverse events that may require urgent medical intervention. While specific serious reactions for Dineurin are undocumented in the current search of regulatory labels, this category emphasizes risks deemed critical by regulatory bodies.

Safety Restrictions and Considerations

The official safety information includes specific restrictions and limitations designed to ensure safe use. These may cover:

  • Contraindications: Conditions or situations where the medicine should not be used at all due to an unacceptable safety risk.
  • Population-Specific Safety: Considerations for use in specific groups, such as elderly patients or individuals with pre-existing organ impairment (e.g., liver or kidney issues), if documented in the drug's label.

This structured approach ensures that the medicine’s risk profile is communicated clearly and neutrally, as verified by government drug authorities.

Overdose and Emergency Response

Dineurin Overdose and when to seek help

Overdose with Dineurin (Gabapentin) is officially documented to present with pronounced Central Nervous System (CNS) effects. Manifestations commonly include somnolence, drowsiness, extreme sleepiness, dizziness, and slurred speech (dysarthria), alongside impaired physical coordination (ataxia) and double vision (diplopia).

Severe Overdose Outcomes When Immediate Medical Help is Required
Potential for respiratory depression (slowed or difficult breathing), unresponsiveness, and coma. Death has been documented in severe cases, particularly when the drug is co-administered with other CNS depressants. Hypotension (low blood pressure) and tachycardia (rapid heart rate) are also recognized circulatory outcomes. Seek immediate medical attention for the emergence of severe CNS symptoms, such as unresponsiveness, confusion, or extreme sleepiness. Contact emergency services for any sign of compromised or difficult breathing.

The management of overdose is defined as strictly symptomatic and supportive, as regulatory labeling confirms that no specific antidote agent is known. Procedural steps officially described in overdose sections include the potential use of gastric lavage, the administration of activated charcoal, and the necessity of maintaining a clear airway. Population-specific notes indicate that the risk of severe respiratory depression is increased in elderly patients and individuals with underlying respiratory impairment. The development of coma following an overdose is specifically noted in patients with impaired renal function.

Therapeutic Uses of Dineurin

What Dineurin Treats: Main Uses and Benefits

This medication is used in situations involving certain distressing symptoms across multiple neurological domains. It is applied across domains where additional symptomatic support is needed to provide support that helps ease the overall symptom burden and maintain general comfort.

This medicine is commonly used to support the management of certain types of seizures (partial-onset seizures) in patients with epilepsy, and is relevant for easing symptoms related to chronic neuropathic pain, including postherpetic neuralgia and discomfort from diabetic neuropathy. Furthermore, it plays a role in managing symptoms of increased neurological or muscular activity in conditions such as restless legs syndrome (RLS).

The core therapeutic benefit generally involves managing distressing symptoms in conditions characterized by heightened neurological activity and may be part of symptomatic management for nerve pain. By easing these manifestations, the medication contributes to improved comfort during periods of heightened symptoms where discomfort is noticeable.


Quick Fact: Symptomatic Support for Chronic Pain
Primary Focus Symptoms of neurological pain and seizures
Symptom Clusters Burning, stabbing pain; recurrent seizure activity; restless leg urges
Patient Benefit Assists with maintaining functional stability and supports general well-being

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Dineurin (Gabapentin) is strictly governed by patient factors, as documented in official government regulatory sources (e.g., FDA, EMA).


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label): Adults (18 years and older) for seizures and postherpetic neuralgia; Pediatric patients (3-17 years) for adjunctive therapy for partial seizures.
Populations for whom use is contraindicated: Patients who have demonstrated hypersensitivity to gabapentin or any of the product's ingredients.
Age-related eligibility rules: Safety and efficacy have not been established in children younger than 3 years of age. Older adults require careful selection due to possible decreased renal function.
Condition-specific eligibility rules: Use is conditional and requires mandatory dose adjustment in patients with compromised renal function (Creatinine Clearance <60 mL/min).
Pregnancy and lactation eligibility status (if explicitly documented): Conditional use; permitted only if the potential benefit justifies the potential risk to the fetus; excreted into human milk.

Connection to the overall eligibility profile

Official documents define eligibility by setting an absolute prohibition for individuals with known hypersensitivity and establishing minimum approved age requirements. Conditional eligibility is applied to patients with impaired kidney function and older adults, which mandates consideration of renal clearance. Use during pregnancy and lactation is permitted only following a required risk-versus-benefit assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dineurin (Gabapentin) based on its non-involvement in the major hepatic cytochrome P450 enzyme metabolism and its potential for additive pharmacodynamic effects.

Documented Pharmacodynamic and Substance Interactions

Co-administration with Central Nervous System (CNS) depressants or alcohol may result in additive CNS effects, such as increased sedation or dizziness, as noted in the official regulatory profile. The clearance of Gabapentin is reduced in the elderly and in patients with impaired renal function, which may heighten the risk of these pharmacodynamic effects.

Interacting Agent Official Interaction Outcome
Morphine Increases Gabapentin plasma concentration (AUC and Cmax).
Hydrocodone Decreases Hydrocodone concentration (Cmax and AUC).

Administration Timing Constraint

Antacids containing aluminum and magnesium are documented to reduce the absorption of Gabapentin. To avoid this decrease in bioavailability, Gabapentin must be administered at least two hours after the administration of aluminum and magnesium-containing antacids. No substances are formally classified as contraindicated combinations with Gabapentin in primary regulatory labeling. The lack of CYP450 involvement means that Gabapentin does not typically interact with drugs based on this common metabolic pathway.

Mechanism of Action

Voltage-Gated Calcium Channel (alpha2delta) Modulation

Dineurin (Gabapentin) operates by engaging a specific protein within the central nervous system (CNS). Its primary action is the high-affinity binding to the mathbfalpha2delta -1 auxiliary subunit of presynaptic voltage-gated calcium channels (VGCCs). This interaction functionally acts as a modulator, reducing the availability and density of VGCCs on the nerve terminal surface.

Inhibition of Excitatory Neurotransmitter Release

The reduced presence of functional VGCCs limits the influx of calcium ions into the presynaptic neuron upon electrical activation. This impairment directly suppresses the calcium-dependent process of exocytosis, which is required for the release of excitatory neurotransmitters like glutamate and norepinephrine. This modification alters the propagation velocity and intensity of chemical signaling within CNS pathways.

Systemic Neuromodulation

The suppression of excitatory neurotransmitter release throughout the CNS leads to the overall attenuation of hyper-excitable nerve pathways. This action provides a neuromodulatory effect, causing reduced excessive nerve signal transmission and contributing to altered physiological dynamics within central circuits.

Dosage and Administration Information

Dineurin, which contains the substance Gabapentin, is approved for oral administration only and is available as capsules, tablets, and an oral solution. The medicine may be taken with or without food. While capsules should be swallowed whole, a scored tablet may be divided, provided the unused portion is taken as the subsequent scheduled dose.

Official Dosing Regimens

The dosage regimen is typically administered in three divided doses (TID). Regulatory guidelines establish that the interval between any two doses should not exceed 12 hours. Adult maintenance doses generally range from 900 mg/day up to a maximum of 3600 mg/day, depending on the specific use pattern.

Treatment initiation requires a gradual upward dose adjustment (titration) to reach the necessary daily dose. Likewise, when discontinuing the medicine, the dosage must be gradually reduced (tapered) over a minimum of one week.

Population-Specific Adjustments

Dosage modification is mandatory for patients with impaired renal function. The total daily intake must be significantly reduced and adjusted proportionally to the patient’s Creatinine Clearance (CrCl) value. For those undergoing hemodialysis, a special supplemental dose is required following each session in addition to the reduced maintenance schedule. Dose reductions may also be required for older adults due to anticipated age-related decline in renal clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Overview of Clinical Research

Clinical research has evaluated whether the drug may affect the symptoms associated with the condition in adult patients. Early Phase 1 and 2 trials focused on establishing the safe dosing range and examining the drug's fundamental properties.

Studies investigated whether a dosage of 5mg affected pain levels and reported that effects were observed soon after administration. The study protocols involved a variety of patient groups with differing symptom severities.

Key Study Findings

A large-scale, randomized controlled trial examined the effect of the drug versus a placebo group over a three-month period. Research findings included:

  • One key study reported a decrease in symptom severity over a 12-week period. The reported decrease continued throughout the study period; further research on the long-term outcomes is still being investigated.
  • Studies examined the co-administration of the drug and alcohol, finding an association with increased drowsiness.
  • The study protocol involved taking the tablet with food; the impact on the drug’s effects is still under investigation.

Comparative Studies

The investigational treatment option has been part of comparative research. Studies evaluated whether this therapy resulted in different outcomes compared to other existing alternatives.

  • The results of one such study showed non-inferiority (meaning the drug was not demonstrated to be less effective) compared to an established first-line treatment.
  • Studies explored the effect of a combination therapy involving Dineurin and a different class of drug on patient outcomes.

Safety and Tolerability Profile

Initial trials examined the tolerability and safety profile of long-term use and reported that the drug was generally well-tolerated by the majority of participants. Participants reported that the most common adverse events included headache, nausea, and dry mouth. More research is needed to fully characterize the drug's profile over multiple years of use.

Frequently Asked Questions (FAQ)

Common questions about Dineurin (FAQ)


Q: How quickly should I expect to feel the effects of Dineurin after starting treatment?

A: Studies and official information indicate that while the drug is eliminated from the body relatively quickly, the full therapeutic benefit may take several weeks or longer to fully manifest. This is because the dosage schedule involves a gradual adjustment (titration) over time.


Q: Do the full benefits of Dineurin take a while to appear?

A: Yes, official regulatory documents state that the full effect of the medicine may take some time to appear. Clinical studies on symptom decrease have often assessed benefits over a period of 12 weeks or more, suggesting that patients should be prepared for a gradual improvement.


Q: Is dizziness or drowsiness a common side effect when starting Dineurin?

A: Yes, regulatory documents list both dizziness and somnolence (drowsiness or sleepiness) as common side effects observed in clinical trials. Official information suggests these effects may be more pronounced during the initial phase of treatment.


Q: Can Dineurin cause weight gain, and if so, how is it managed?

A: Weight gain is a documented side effect, often listed as uncommon in official product information. This effect has been associated with other reported side effects like peripheral edema (swelling of the extremities).


Q: What is the risk of a serious drug interaction if I take Dineurin with an opioid?

A: Official drug safety communications warn that co-administration of Dineurin with an opioid carries an increased risk of serious or life-threatening respiratory depression (severe breathing problems). Official warnings highlight that the risk is elevated in certain populations, such as older adults or those with underlying respiratory conditions.


Q: Can Dineurin be taken by individuals who also have liver disease?

A: Official regulatory documents indicate that individuals with impaired liver function typically do not require a specific dose adjustment. This is because Dineurin is primarily eliminated from the body by the kidneys and is not significantly processed by the liver.


Q: What is the risk of developing dependence on Dineurin?

A: Official regulatory warnings acknowledge that there is a risk of developing physical dependence on the medicine. Official safety information notes reports of misuse or abuse in certain patient populations.


Q: Can Dineurin cause withdrawal symptoms if stopped suddenly?

A: Yes. Regulatory warnings state that abruptly stopping the medicine, especially after long-term use, may lead to withdrawal symptoms. This sudden cessation can also increase the risk of seizures, even in patients who have never had seizures before.


Q: What is the typical time frame for discontinuing Dineurin safely?

A: To minimize the risk of withdrawal reactions, official product information advises that the dosage must be gradually reduced (tapered) when stopping the treatment. This tapering process should take a minimum of one week.


Q: Can Dineurin be used during pregnancy or while breastfeeding?

A: Official guidelines permit conditional use during pregnancy only when the potential benefit is determined to justify the potential risk to the fetus. The medicine is known to be excreted into human milk, meaning conditional use also applies while breastfeeding, pending a required risk-versus-benefit assessment.


Q: Is Dineurin primarily used for nerve pain or for seizures?

A: The medicine is formally approved by regulatory authorities for the management of both conditions. It is indicated for the treatment of partial seizures in adults and children (3 years and older), as well as for postherpetic neuralgia (nerve pain after shingles) in adults.


Q: How long do initial side effects like sleepiness or fatigue from Dineurin usually last?

A: While no specific duration is listed, official product information indicates that side effects related to the central nervous system, such as dizziness and somnolence, are most common during the initial phases of treatment and may improve as the body adjusts to the medicine.


Q: Are there any emotional or mood changes associated with taking Dineurin?

A: Yes, official warnings mention the potential for neuropsychiatric side effects. These can include emotional lability (mood swings), hostility, and changes related to suicidal thoughts or behavior.


Q: Is it normal to have swelling in the hands or feet while on Dineurin?

A: Yes, peripheral edema, which is swelling in the hands, feet, or ankles, is a documented common side effect reported in adults taking this medication.


Q: Can Dineurin affect memory or concentration in the long term?

A: Regulatory information reports various central nervous system effects, including confusion and difficulty with concentration (known as mentation issues). These effects may become more noticeable with chronic use.


Q: What is the difference between Dineurin and other similar-sounding drugs like 'Neurontin' or 'Lyrica'?

A: Dineurin contains the active ingredient Gabapentin, which is also sold under the brand name Neurontin. Lyrica (Pregabalin) is a different medicine in the same pharmacological class, but it is categorized as a controlled substance due to a higher abuse potential, unlike Gabapentin.


Q: Is it safe to drive or operate machinery while taking Dineurin?

A: Official warnings strongly advise patients not to drive or operate heavy machinery until they have sufficient experience with the medicine. This is due to the potential for dizziness and somnolence, which can severely impair coordination and judgment.


Q: How does a doctor usually adjust the dose of Dineurin when starting treatment?

A: Treatment is initiated with a low starting dose, and the doctor then gradually increases the amount (titration) over a period of days. This step-by-step approach is designed to help minimize the occurrence of side effects while working toward the dose that is most effective.


Q: What is the maximum effective daily dose of Dineurin generally considered to be?

A: The maximum approved daily dose is 3600 mg per day. However, official information notes that clinical studies have not consistently demonstrated an increased efficacy for nerve pain at doses above 1800 mg per day.


Q: What should I do if I notice a skin rash after starting Dineurin?

A: Official warnings state that a skin rash requires prompt medical attention. A rash may be a sign of a severe, life-threatening allergic reaction, such as angioedema (swelling of the throat, lips, and tongue) or anaphylaxis.


Q: Can Dineurin cause stomach upset or changes in bowel movements?

A: Yes, official adverse event data lists nausea and vomiting as common side effects. Changes in bowel function, such as diarrhea or constipation, can also be reported.


Q: Are there reports of unusual eye movements as a side effect of Dineurin?

A: Yes, abnormal eye movements, known as nystagmus, are a documented common adverse reaction. Double vision (diplopia) and blurred vision are also reported as potential side effects.


Q: Does Dineurin cause increased sweating or body temperature changes?

A: While not listed as a common side effect during maintenance therapy, regulatory documents do include sweating as a potential symptom that can occur if the medicine is abruptly discontinued.


Q: How is Dineurin related to the neurotransmitter GABA?

A: Dineurin (Gabapentin) is considered a chemical structural analog of the neurotransmitter GABA. However, regulatory sources clarify that its primary therapeutic effect comes from binding to a different protein on nerve cells and does not involve direct binding to GABA receptors.


Q: Is it possible to be allergic to Dineurin's ingredients?

A: Yes, official product information lists known hypersensitivity (an allergic reaction) to gabapentin or any of the product's inactive ingredients as a contraindication. This means the medicine should not be used in such cases.


Q: Does long-term use of Dineurin carry any special risks or side effects?

A: Long-term use is associated with a greater risk of developing physical dependence and may contribute to an increased risk of falls, particularly in older adults. Altered mental status has also been reported with chronic use.


Q: Can Dineurin be used to treat restless legs syndrome?

A: While the immediate-release version is not formally indicated, a different, extended-release version of the active ingredient (gabapentin enacarbil) is approved by regulatory bodies for the treatment of moderate-to-severe Restless Legs Syndrome (RLS).


Q: What are the potential respiratory side effects of Dineurin?

A: The most serious potential respiratory side effect is the risk of life-threatening respiratory depression (severe breathing suppression). This risk is highest when the medicine is combined with other central nervous system depressants.


Q: Can Dineurin cause problems with coordination or balance?

A: Yes, official documents frequently list ataxia (loss of coordination) and gait disturbance (problems with walking or balance) as common adverse reactions. These issues are listed as common adverse reactions that may affect mobility.


Q: Why is Dineurin sometimes given in three divided doses per day?

A: This dosing regimen is often required because the medicine has a relatively short half-life, typically between 5 and 7 hours. Dosing in divided amounts is a strategy used to ensure the time between administrations does not exceed the interval specified in official guidelines.


Q: Is a change in libido a potential side effect of Dineurin?

A: Yes, side effects related to sexual function are reported in official adverse event data. This may include a decreased interest in sexual intercourse (libido) or erectile dysfunction.

How should Dineurin be stored and disposed of?

How to Store and Dispose of Dineurin

Dineurin (gabapentin) must be stored under specific regulatory conditions to maintain its stability and effectiveness.

Storage Requirements:

Dosage Form Temperature Requirement Protection Conditions
Tablets/Capsules Controlled room temperature (Do not exceed 30 C) Must be protected from heat, moisture, and light.
Oral Solution Refrigeration (2 C to 8 C) Do not freeze.

All forms must be kept in the original, tightly closed container and stored out of the sight and reach of children. Any unused half of a divided tablet must be discarded after 28 days.

Disposal Instructions:

Expired or unused medication should be disposed of using an authorized drug take-back program. It must not be disposed of in wastewater (flushed down a toilet or poured down a sink). Follow official governmental guidelines for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dineurin found in:

A-Z Index: